| 2.24 -0.05 (-2.18%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.26 | 1-year : | 3.93 |
| Resists | First : | 2.79 | Second : | 3.36 |
| Pivot price | 2.38 |
|||
| Supports | First : | 1.86 | Second : | 1.54 |
| MAs | MA(5) : | 2.37 |
MA(20) : | 2.4 |
| MA(100) : | 2.88 |
MA(250) : | 5.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.6 |
D(3) : | 39.1 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 16.73 | Low : | 1.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FNCH ] has closed above bottom band by 35.7%. Bollinger Bands are 20.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.31 - 2.33 | 2.33 - 2.34 |
| Low: | 2.07 - 2.09 | 2.09 - 2.1 |
| Close: | 2.22 - 2.24 | 2.24 - 2.26 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Wed, 17 Apr 2024
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day ... - Markets Insider
Mon, 01 Apr 2024
5 Best Microbiome Companies (April 2024) - Securities.io
Tue, 12 Mar 2024
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Markets Insider
Sat, 24 Feb 2024
Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation - TipRanks.com - TipRanks
Wed, 22 Nov 2023
Billionaire Seth Klarman's Biotech Stock Picks - Yahoo Finance
Mon, 12 Jun 2023
Finch Therapeutics, FNCH, down 90% in a year, up 3,000% this morning - why? - Dhaka Tribune
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 792860 (%) |
| Held by Institutions | 53.4 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.248e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -31 % |
| Return on Assets (ttm) | 777.5 % |
| Return on Equity (ttm) | -19.5 % |
| Qtrly Rev. Growth | 107000 % |
| Gross Profit (p.s.) | -217.4 |
| Sales Per Share | -274.05 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -46.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.07 |
| Dividend | 0 |
| Forward Dividend | 9150 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|